C-reactive protein-to-lymphocyte ratio is a novel biomarker for predicting the long-term efficacy of ustekinumab treatment in ulcerative colitis
The baseline C-reactive protein-to-lymphocyte ratio value and early treatment response are useful biomarkers to predict the long-term efficacy of ustekinumab treatment.
Authors
- Kazuhide Higuchi (ORCID: https://orcid.org/0000-0002-4142-2272)
- Kazuki Kakimoto (ORCID: https://orcid.org/0000-0003-0564-2793)
- Keijiro Numa (ORCID: https://orcid.org/0009-0003-6081-5287)
- Shirô Nakamura (ORCID: https://orcid.org/0000-0003-4435-1294)
- Hiroki Nishikawa (ORCID: https://orcid.org/0000-0003-3489-2740)
- Noboru Mizuta
- Ryoji Koshiba (ORCID: https://orcid.org/0009-0003-6607-0589)
- Kei Nakazawa (ORCID: https://orcid.org/0000-0002-0086-0671)
- Yuki Hirata (ORCID: https://orcid.org/0000-0002-3686-4690)
- Takako Miyazaki (ORCID: https://orcid.org/0000-0003-3255-4932)
- Naohiko Kinoshita (ORCID: https://orcid.org/0000-0002-8074-2834)
Institutions
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1371/journal.pone.0305324
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.55